the clinical significance of β-arrestin 2 expression in the serum of 
non-small cell lung cancer patients

Clicks: 200
ID: 194597
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #77 of 101 articles by views in proceedings of the 10th acm multimedia systems conference, mmsys 2019

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Background and objective Non-small cell lung cancer (NSCLC) with high morbidity and mortality is the most common types of lung cancer. beta-arrestin 2 is a kind of soluble protein regulating signal transduction mediated by G protein coupling receptor. The aim of this research is to evaluate the clinical significance of β-arrestin 2 expression in the serum of NSCLC patients. Methods The clinical and follow-up data of 20 healthy candidates and 67 patients diagnosed with NSCLC in Sun Yat-sen University Cancer Center from January 2005 to December 2006 was retrospectively analyzed. ELISA was applied to detect the expression of beta-arrestin 2. Results The serum level of β-arrestin 2 in NSCLC patients were all significally lower than those in healthy controls (P<0.001, P<0.001, P<0.001). The serum level of β-arrestin 2 in stage I NSCLC patients were higher than those in stage III as well as in stage IV (P<0.001, P<0.001). No statistical difference of β-arrestin 2’ serum level was found between with stage III and stage IV patients (P=0.273). Univariate prognostic factor analyzed by Kaplan-Meier method indicated patients’ prognosis with high serum level of β-arrestin 2 was better than patients with low and middle (P<0.001, P<0.001). The serum level of β-arrestin 2 and the stage of NSCLC signally affected prognosis in COX regression model (P=0.003, P=0.004). Conclusion The serum level of β-arrestin 2 had significant difffrence between NSCLC patients and healthy controls, likewise between the early and advanced NSCLC patients. The serum level of β-arrestin 2 affected NSCLC patients’ prognosis.
Reference Key
wu2011chinesethe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Zhengqing WU, Wenxia Tong, Zihui Tan, Siyu Wang, Peng Lin
Are you one of these authors? Claim your profile
Journal proceedings of the 10th acm multimedia systems conference, mmsys 2019
Year 2011
DOI
10.3779/j.issn.1009-3419.2011.06.04
URL
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.06.04
Keywords
lung neoplasms Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.